Achieve Life Sciences, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Achieve Life Sciences, Inc. (ACHV) reported Restructuring and Related Cost, Number of Positions Eliminated of 5 Position for the 1-month period ending 2016-11-30, per its 10-Q filed 2017-07-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2017-07-31
- 2016-02-29: Restructuring and Related Cost, Number of Positions Eliminated 1 month 11.00 Employee.
Employee
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month |
|---|---|
| 2016-02-29 | 11.00 Employee 10-Q · filed 2017-07-31 |
Position
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month |
|---|---|
| 2016-11-30 | 5.00 Position 10-Q · filed 2017-07-31 |
| 2016-10-31 | 14.00 Position 10-Q · filed 2017-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |